Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment

Advances in Experimental Medicine and Biology

Volumn 431, Issue , 1998, Pages 13-18

  Yamanaka, Hisashi ^a   Togashi, Riko ^a   Hakoda, Masayuki ^a   Terai, Chihiro ^a   Kashiwazaki, Sadao ^a   Dan, Takashi ^b   Kamatani, Naoyuki ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; COLCHICINE; NONSTEROID ANTIINFLAMMATORY AGENT; URIC ACID;

CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; GOUT; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; REFERENCE VALUE; RISK ASSESSMENT; STATISTICAL ANALYSIS; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL;

EID: 0031863414     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-5381-6_3     Document Type: Conference Paper

References (5)

1. Wallace SL, Singer JZ. Therapy in gout. Rheum Dis Clin North Am 14, 441-457, 1988
2. Paulus HE, Schlosstein LH, Godfrey RC, Klinenberg JR, Bluestone R: Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients. Arthritis Rheum 17, 609-614, 1974
3. Kot TV, Day RO, Brooks PM: Preventing acute gout when starting allopurinol therapy. Colchicine or NSAIDs? Med J Aust 159, 182-184, 1993
4. Terkeltaub RA: Pathogenesis and treatment of crystal induced inflammation. In, Arthritis and Allied Conditions. Twelfth edition. Edited by DJ McCarty, WJ Koopman. Philadelphia, Lea & Febiger, 1993
5. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu T-F: Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 20, 895-900, 1977